{
  "docId": "019de071-3aad-716d-87e6-57feca2aeaf3",
  "docSlug": "2b4775a08c8e376708f38bde257340c9",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 42,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 14,
  "notes": "Includes a Kaplan-Meier survival curve for the OlympiaA trial.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-3aad-716d-87e6-57feca2aeaf3/31",
  "deckHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3",
  "deckJsonHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3.json",
  "deckAnchorHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.52,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Lynparza demonstrated a sustainable and clinically meaningful treatment effect compared to placebo",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b0f1874-38ce-4469-b8aa-76b9b5d803eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "list",
      "text": "2021 ASCO Annual Meeting: another strong presence - 90 abstracts and 74 presentations. One plenary session, 12 oral presentations, 14 poster discussions, 47 posters, 16 abstracts. Calquence ELEVATE-TN and ELEVATE-RR. Imfinzi PACIFIC. Enhertu pipeline.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85947793-8d39-47c0-b3b8-ddafcfe6381b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1. 24 additional presentations at ASCO 2021 featured AstraZeneca medicines and potential new medicines but were not supported by AstraZeneca. Source: ASCO 2021 accepted abstracts. 2. With germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. Source: ASCO 2021 accepted abstracts. Abstract LBA01, plenary session, ASCO 2021.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb9960dd-1d40-4b9c-a2a4-402c220a0118",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.03,
        "y": 0.11
      },
      "kind": "title",
      "text": "Further solid progress in redefining cancer care",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "295ac74d-46e3-49a2-8397-bf3ac8bfc543",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Oncology: 2021 ASCO Annual Meeting",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "068adf41-46dc-4158-b756-c1fe1784c6bf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "3565d355-c4ff-49e4-953b-db9069858432",
      "evidence": "Oncology: 2021 ASCO Annual Meeting",
      "confidence": 0.7
    },
    {
      "name": "Call to action",
      "slug": "call-to-action",
      "agent": null,
      "layer": "slide",
      "matchId": "a503fd5d-d70e-4f4d-9adc-f54a493d7f3d",
      "evidence": "Further solid progress in redefining cancer care",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 37,
      "from": 21,
      "beatId": "e153daee-719b-4113-901b-2398e780892e",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The document outlines the company's strategic journey and pipeline progress",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 34,
      "from": 28,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "9d4065ae-e52c-4e8c-881b-127f335a2ea1",
      "evidence": "The document highlights the risks of not investing in pipeline development",
      "position": 1,
      "objective": "Emphasizing the importance of pipeline progress and news flow",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}